皮下注射胰高血糖素样肽-1联合胰岛素可使1型糖尿病患者餐后血糖波动恢复正常。 - Suppr

Suppr

超能文献

Subcutaneous glucagon-like peptide I combined with insulin normalizes postcibal glycemic excursions in IDDM.

作者信息

Dupré J, Behme M T, Hramiak I M, McDonald T J

出版信息

Diabetes Care. 1997 Mar;20(3):381-4. doi: 10.2337/diacare.20.3.381.

DOI:10.2337/diacare.20.3.381

PMID:9051391

Abstract

摘要

相似文献

Subcutaneous glucagon-like peptide I combined with insulin normalizes postcibal glycemic excursions in IDDM.皮下注射胰高血糖素样肽-1联合胰岛素可使1型糖尿病患者餐后血糖波动恢复正常。

Diabetes Care. 1997 Mar;20(3):381-4. doi: 10.2337/diacare.20.3.381.

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.持续皮下输注胰高血糖素样肽-1可降低2型糖尿病患者的血糖水平并减少食欲。

Diabetes Care. 1999 Jul;22(7):1137-43. doi: 10.2337/diacare.22.7.1137.

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.外源性胰高血糖素样肽I（7-36）酰胺在I型糖尿病患者中的血糖稳定作用及空腹高血糖的降低

Diabetes Care. 1996 Jun;19(6):580-6. doi: 10.2337/diacare.19.6.580.

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.胰高血糖素样肽-1（7-36）酰胺对正常受试者和糖尿病患者的抗糖尿病作用。

N Engl J Med. 1992 May 14;326(20):1316-22. doi: 10.1056/NEJM199205143262003.

Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.皮下注射胰高血糖素样肽-1可改善早期2型糖尿病患者3周内的餐后血糖控制。

Clin Sci (Lond). 1998 Sep;95(3):325-9.

Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.皮下注射短效胰岛素类似物后，病程短且残余胰岛β细胞功能的胰岛素依赖型糖尿病患者餐后代谢控制得到改善。

Diabetes Care. 1995 Nov;18(11):1452-9. doi: 10.2337/diacare.18.11.1452.

Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes.艾塞那肽-4使1型糖尿病患者进食后血糖波动正常化。

J Clin Endocrinol Metab. 2004 Jul;89(7):3469-73. doi: 10.1210/jc.2003-032001.

Glucagon-glucose (GG) test for the estimation of the insulin reserve in diabetes.

Diabetes Res Clin Pract. 1992 Nov;18(2):99-105. doi: 10.1016/0168-8227(92)90005-c.

Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.

Diabetes. 1995 Jun;44(6):626-30. doi: 10.2337/diab.44.6.626.

Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes.胰高血糖素样肽1（7-36）酰胺对2型糖尿病患者葡萄糖有效性及胰岛素作用的影响

Diabetes. 2000 Apr;49(4):611-7. doi: 10.2337/diabetes.49.4.611.

引用本文的文献

Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes.西格列汀和米格列醇联合治疗对胰岛素治疗的 2 型糖尿病的影响。

Diabetes Ther. 2012 Nov;3(1):11. doi: 10.1007/s13300-012-0011-x. Epub 2012 Sep 28.

Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus.GLP-1 及其激动剂在 1 型糖尿病治疗中的可能作用。

Curr Diab Rep. 2012 Oct;12(5):560-7. doi: 10.1007/s11892-012-0291-6.

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.利拉鲁肽治疗 4 周可减少 1 型糖尿病患者（无论是否存在残留β细胞功能）的胰岛素剂量，而不会导致血糖控制丢失。

Diabetes Care. 2011 Jul;34(7):1463-8. doi: 10.2337/dc11-0096. Epub 2011 May 18.

Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.1 型糖尿病患者β细胞功能尚存和丧失时内源性和外源性 GLP-1 的抗糖尿病作用。

Diabetes. 2011 May;60(5):1599-607. doi: 10.2337/db10-1790. Epub 2011 Mar 25.

Glucagon-like peptide 1 improved glycemic control in type 1 diabetes.胰高血糖素样肽1改善了1型糖尿病患者的血糖控制。

BMC Endocr Disord. 2003 Apr 10;3(1):3. doi: 10.1186/1472-6823-3-3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验